Inventiva to present new lanifibranor Phase 3 NATiV3 MASH trial data in Q4 update, AASLD abstracts show

PUBT · 2d ago
Inventiva to present new lanifibranor Phase 3 NATiV3 MASH trial data in Q4 update, AASLD abstracts show
  • Inventiva announced three scientific posters on lanifibranor for MASH will be presented at AASLD The Liver Meeting 2026.
  • New preclinical analyses indicate the drug acts across multiple liver cell types, supporting a broad anti-fibrotic rationale.
  • Additional preclinical work, supported by earlier Phase 2b results, suggests improvements in endothelial dysfunction tied to vascular abnormalities across disease stages.
  • A separate plasma cfDNA analysis in MASLD points to coordinated epigenetic disruption across PPAR pathways, backing a pan-PPAR approach.
  • Lanifibranor remains in the Phase 3 NATiV3 trial, with topline results expected in the fourth quarter of this year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061605PRIMZONEFULLFEED1001276625) on October 06, 2026, and is solely responsible for the information contained therein.